Hipod-CV 50 XL Oral Suspension is a combination antibiotic formulation containing Cefpodoxime Proxetil 50 mg and Clavulanic Acid 31.25 mg per dose, designed for the treatment of a broad spectrum of bacterial infections. Cefpodoxime Proxetil, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, effective against various Gram-positive and Gram-negative pathogens. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefpodoxime by preventing enzymatic degradation of the antibiotic, thereby extending its spectrum to include beta-lactamase producing resistant strains. Hipod-CV 50 XL Oral Suspension is indicated for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial infections. The extended-release formulation ensures sustained plasma concentrations, improving patient compliance through reduced dosing frequency. Administration should follow prescribed dosage regimens based on infection severity and patient-specific factors. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Hypersensitivity reactions, although rare, warrant immediate medical attention. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Hipod-CV 50 XL Oral Suspension should be used under medical supervision to ensure optimal therapeutic outcomes and to minimize the risk of antimicrobial resistance.